Skip to main content
Eledon Pharmaceuticals, Inc. logo

Eledon Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ELDN ISIN · US67011N2045 LEI · 549300S17CAM13O43606 US Professional, scientific and technical activities
Open in API
Filings indexed 585 across all filing types
Latest filing 2017-08-18 Proxy Solicitation & In…
Country US United States of America
Listing US ELDN

About Eledon Pharmaceuticals, Inc.

https://eledon.com/

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing immune-modulating therapies for organ transplantation and autoimmune diseases. The company's mission, "One Transplant for Life," focuses on improving transplant longevity and the quality of life for recipients. Its lead product candidate, tegoprubart, is an anti-CD40 Ligand (CD40L) antibody designed to regulate the immune system to prevent organ rejection. Eledon has completed a Phase 2 clinical trial evaluating tegoprubart in kidney transplant recipients and is advancing the compound into late-stage development. The company is also exploring tegoprubart's potential in other applications, including liver transplantation and xenotransplantation.

Recent filings

Filing Released Lang Actions
DEF 14A
Proxy Solicitation & Information Statement
2017-08-18 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated August 9, 2017. It announces the financial results for the quarter ended June 30, 2017, and includes a press release as Exhibit 99.1. The text explicitly states that the press release is furnished as an exhibit and incorporated by reference, indicating this document is an announcement of financial results rather than the full financial report itself. The document length is 3379 characters, which is relatively short and consistent with an earnings release announcement rather than a full quarterly report. Therefore, this document fits the definition of an Earnings Release (ER) as it is the initial announcement of quarterly financial results with key highlights only.
2017-08-10 English
Regulatory Filings 2017
Regulatory Filings
2017-08-10 English
FORM 10-Q
Interim / Quarterly Report Q2 2017
2017-08-09 English
Regulatory Filings 2017
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of the effective time for a Registration Statement on Form S-3. It is a formal communication related to a securities registration process, specifically a request under Rule 461 of the Securities Act. The document does not contain financial statements, audit information, or detailed report content. It is a regulatory communication related to capital raising but is not itself a capital/financing update or a report. Given its nature as a formal regulatory filing communication and its short length (1217 characters), it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory documents that do not fit other specific categories.
2017-08-07 English
Regulatory Filings 2017
Regulatory Filings Classification · 95% confidence The document is a letter from a law firm to the SEC responding to comments on a Registration Statement on Form S-3 filed by Novus Therapeutics, Inc. It discusses amendments to the S-3 registration statement and clarifications regarding selling security holders and incorporation by reference of other filings. There is no financial data, earnings information, or report content; rather, it is a regulatory correspondence related to a registration statement filing. The document length is short (3568 characters) and it is clearly a response letter to SEC comments, which fits the category of Regulatory Filings (RNS) as a fallback for miscellaneous regulatory correspondence that does not fit other categories.
2017-08-03 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.